News

Check out market updates

Miragen licenses engineering platform for use in future flagship drug candidate

BOULDER — Miragen Therapeutics Inc. (Nasdaq: MGEN) has licensed a protein-engineering platform from California-based Xencor Inc. (Nasdaq: XNCR) as part […]
Source: BizWest

Leave a Reply

Your email address will not be published. Required fields are marked *

X